Skip to content

Gemigliptin

ALIMENTARY TRACT AND METABOLISM

Also known as: LC15-0444, zemiglo

Korean Food and Drug Administration (KFDA) approvedATC A10BD18ATC A10BD30ATC A10BH06

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Gemigliptin is a drug catalogued in DrugCentral. It was first approved by the Korean Food and Drug Administration (KFDA) in 2012. DrugCentral lists 2 molecular targets, including DPP4 and DPP9. Recorded indications include Diabetes mellitus type 2.

  • Molecular targets: DPP4 and DPP9 (2 listed in DrugCentral).
  • Indications: Diabetes mellitus type 2.
  • ATC code: A10BD18 (Combinations of oral blood glucose lowering drugs).
  • Molecular formula: C18H19F8N5O2; molecular weight 489.37 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Diabetes mellitus type 2

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Dipeptidyl peptidase 4DPP4inhibitorIC50 7.80
Dipeptidyl peptidase 9DPP9unknownIC50 4.33

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2012-06-27Korean Food and Drug Administration (KFDA)——

ATC classification

ATC codeTherapeutic hierarchy
A10BD18ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs
A10BD30ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Combinations of oral blood glucose lowering drugs
A10BH06ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH52ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Dipeptidyl peptidase 4 (DPP-4) inhibitors

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Gemigliptin is on its molecule page.

Molecular formulaC18H19F8N5O2
Molecular weight489.37 g/mol
CAS number911637-19-9
InChIKeyZWPRRQZNBDYKLH-VIFPVBQESA-N
PubChem CID11953153
N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCC2=C(N=C(N=C2C1)C(F)(F)F)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Gemigliptin used for?

DrugCentral lists the following indications for Gemigliptin: Diabetes mellitus type 2.

How does Gemigliptin work?

Its molecular targets in DrugCentral include DPP4 (inhibitor) and DPP9.

When was Gemigliptin first approved?

Gemigliptin was first approved by the Korean Food and Drug Administration (KFDA) in 2012.

What is the chemical formula of Gemigliptin?

Gemigliptin has the molecular formula C18H19F8N5O2 and a molecular weight of 489.37 g/mol.

Browse: all drugs starting with G · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2012-06-27
AgencyKorean Food and Drug Administration (KFDA)
Targets2
Indications1
FormulaC18H19F8N5O2
DrugCentral ID4833
Interactive profile